ACT Accelerator Secures 120 Million $5 COVID-19 Rapid Tests for Low- and Middle-Income Countries
The World Health Organization and partners announced on Monday, September 28, 2020, agreements to supply 120 million COVID-19 antigen rapid tests to low- and middle-income countries at a maximum price of US$5 each.
- Agreements brokered by the ACT-Accelerator will make 120 million antigen rapid diagnostic tests available to low- and middle-income countries over six months, priced at no more than US$5 per unit.
- The tests, made by Abbott and SD Biosensor, return results in 15–30 minutes and can be used outside laboratories, where PCR testing depends on equipment and trained personnel that many countries lack.
- The Global Fund has committed an initial US$50 million, and rollout to up to 20 African countries is planned to begin in October 2020.
ACT Accelerator announces package with eight named organizations and two volume guarantee agreements
The package was announced by the Access to COVID-19 Tools (ACT) Accelerator, whose diagnostics pillar is co-convened by FIND and the Global Fund and works with the World Health Organization and more than 30 partner organizations. The Organizations named in the announcement, according to the WHO news release, include Africa CDC, the Bill & Melinda Gates Foundation, the Clinton Health Access Initiative, FIND, the Global Fund, Unitaid and WHO.
Two volume guarantee agreements sit at the center of the deal. The Gates Foundation executed separate arrangements with manufacturers Abbott and SD Biosensor, who will supply the tests at the guaranteed ceiling price over a six-month period, WHO said. Abbott is contributing its Panbio COVID-19 rapid antigen test along with its Sympheos digital solution, according to the company’s executive vice president for rapid and molecular diagnostics, Andrea F. Wainer.
Why 15 minutes changes testing capacity
Molecular PCR tests detect the virus reliably but require laboratory infrastructure and trained health workers, and results can take hours or days. The antigen tests, by contrast, are highly portable and easy to administer, making near-person, decentralized testing possible in clinics, villages and towns. That distinction matters most where community transmission is widespread and diagnostic capacity is thin.
WHO formalized this clinical judgment in guidance published on September 11, 2020, which highlighted the value of antigen tests in areas where nucleic acid amplification-based diagnostic testing is unavailable or results are significantly delayed. The agency said the tests can support test-trace-isolate strategies, help identify or confirm new outbreaks, monitor disease trends and potentially be used to screen asymptomatic contacts.
“Antigen tests are an important complement to PCR testing, and are crucial to expand testing capacity throughout Africa. The beauty of antigen testing is that it is fast and gives quick results,” said Dr John Nkengasong, Director of the Africa CDC, adding that rapid results will allow healthcare workers to quickly isolate and treat cases while tracing contacts to cut the transmission chain.
US$50 million in first orders
Money and logistics came with the announcement, not after it. The Global Fund said it has made an initial US$50 million available from its COVID-19 Response Mechanism to let countries buy at least 10 million tests at the guaranteed price, with first orders expected to be placed this week through its pooled procurement mechanism.
Unitaid and Africa CDC will combine resources to begin distributing the tests in up to 20 African countries starting in October 2020, an intervention still undergoing final sign-off by their boards, according to the WHO release.
That effort is designed to draw in partners already active in the response, including CHAI, the African Society for Laboratory Medicine and local organizations, and to strengthen the African Union's Partnership to Accelerate COVID-19 Testing (PACT) initiative, launched in August 2020.
Speed the field has never matched
The WHO-led assessment pathway is also moving at record pace. Several rapid antigen tests are being evaluated for WHO Emergency Use Listing, and the first EUL-approved antigen test emerged within eight months of the virus’s identification, WHO said. By comparison, it took nearly five years to develop the first rapid diagnostic test for HIV.
The broader target is larger still: the Diagnostics Pillar aims to facilitate supply of 500 million tests to low- and middle-income countries within 12 months. Several more antigen tests remain under EUL review.
“High-quality rapid tests show us where the virus is hiding, which is key to quickly tracing and isolating contacts and breaking the chains of transmission. The tests are a critical tool for governments as they look to reopen economies and ultimately save both lives and livelihoods,” said Dr Tedros Adhanom Ghebreyesus, Director General of WHO.
Director General
Funding gaps that remain
Partner organizations framed the announcement as necessary but not sufficient. Dr Catharina Boehme, Chief Executive Officer of FIND, said substantial new funding from public, philanthropic and multilateral sources is urgently needed to reach everyone who needs testing and bring prices down further.
For healthcare systems weighing how to integrate antigen testing into screening and outbreak protocols, guidance from public health agencies and consultation with qualified infectious disease and laboratory medicine specialists remains the practical route to correct deployment.
Purchase orders ship this week and African test distribution begins next month
First purchase orders go out this week. Test distribution across African countries begins next month. The ACT-Accelerator, set up in response to a call from G20 leaders in March 2020 and launched in April 2020 by WHO, the European Commission, France and the Gates Foundation, positions these diagnostic milestones to complement expected results from its vaccine and therapeutics pillars.
Peter Sands, Executive Director of the Global Fund, put the scale of the collaboration plainly: “This is not just a new test – it’s the money and the deployment plan to get it to where it’s needed, fast. This is the power of global collaboration.”